At Novartis, we actively nurture a culture of giving and volunteering with our associates. Here’s how our people are making a difference around the world and why they volunteer. We empower our people ...

Novartis works with the patient community around the world to discover new ways to improve and extend people’s lives. Novartis works closely with healthcare professionals around the world to support ...

April 26, 2023 Today Novartis has published updated 2022 quarterly and full year segment financials reflecting transfers of Sandoz biotechnology manufacturing services to other companies’ activities ...

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the ...

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the ...

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the ...

The project is structured such that a multi-disciplinary health professional team will provide tailored care for patients, aligned with the Primary Care Networks (PCNs) Contract Direct Enhanced ...

A Phase 2, Adaptive, Randomized, Open-label, Assessor-blinded Active-controlled Study to Evaluate the Efficacy and Safety of Rapcabtagene Autoleucel Versus Standard of Care in Patients Suffering From ...

Das Novartis School Lab bietet Jugendlichen im Alter von 16 bis 19 Jahren die Möglichkeit, kostenfrei praktische Experimente zur Gentechnik zu erleben. Die Life Science Week umfasst einen viertägigen ...

Sr. Spec. DDIT IES Cloud Engineering Regular, Full time Universal Hierarchy Node India +Alternative Locations Hyderabad (Office) Giu 05, 2025 Assoc. Dir. DDIT IES Cloud Engineering Regular, Full time ...

FDA approval based on robust Phase III data in which Cosentyx ® (secukinumab) showed rapid relief from symptoms of hidradenitis suppurativa (HS) as early as Week 2 1 As the only IL-17A inhibitor ...